首页> 外文期刊>Clinical chemistry and laboratory medicine: CCLM >Utility of procalcitonin, C-reactive protein and white blood cells alone and in combination for the prediction of clinical outcomes in community-acquired pneumonia
【24h】

Utility of procalcitonin, C-reactive protein and white blood cells alone and in combination for the prediction of clinical outcomes in community-acquired pneumonia

机译:降钙素原,C反应蛋白和白细胞单独使用或联合使用可预测社区获得性肺炎的临床结局

获取原文
获取原文并翻译 | 示例
           

摘要

Background: The added value of biomarkers, such as procalcitonin (PCT), C-reactive protein (CRP), and white blood cells (WBC), as adjuncts to clinical risk scores for predicting the outcome of patients with community-acquired pneumonia (CAP) is in question. We investigated the prognostic accuracy of initial and follow-up levels of inflammatory biomarkers in predicting death and adverse clinical outcomes in a large and well-defined cohort of CAP patients.
机译:背景:降钙素原(PCT),C反应蛋白(CRP)和白细胞(WBC)等生物标志物的附加值可作为临床风险评分的辅助指标,以预测社区获得性肺炎(CAP)患者的结局)有问题。我们调查了炎症生物标志物的初始和随访水平在预测大量CAP患者中的死亡和不良临床结局时的预后准确性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号